Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

被引:0
|
作者
Geraldine O.’Sullivan Coyne
Lihua Wang
Jennifer Zlott
Lamin Juwara
Joseph M. Covey
Jan H. Beumer
Mihaela C. Cristea
Edward M. Newman
Stephen Koehler
Jorge J. Nieva
Agustin A. Garcia
David R. Gandara
Brandon Miller
Sonny Khin
Sarah B. Miller
Seth M. Steinberg
Larry Rubinstein
Ralph E. Parchment
Robert J. Kinders
Richard L. Piekarz
Shivaani Kummar
Alice P. Chen
James H. Doroshow
机构
[1] National Cancer Institute,Division of Cancer Treatment and Diagnosis
[2] Frederick National Laboratory for Cancer Research,Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate
[3] Frederick National Laboratory for Cancer Research,Clinical Monitoring Research Program, Clinical Research Directorate
[4] University of Pittsburgh School of Pharmacy,Department of Pharmaceutical Sciences
[5] City of Hope National Medical Center,Department of Medical Oncology and Therapeutics Research
[6] City of Hope Medical Group,Center for Cancer Research
[7] University of Southern California Norris Comprehensive Cancer Center,undefined
[8] University of California Davis Cancer Center,undefined
[9] National Cancer Institute,undefined
[10] Louisiana State University,undefined
来源
关键词
DNMT1 inhibitors; Cancer epigenetics; Epigenetic modifying agents; Circulating tumor cells; p16;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:979 / 993
页数:14
相关论文
共 5 条
  • [1] Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors
    Coyne, Geraldine O. 'Sullivan
    Wang, Lihua
    Zlott, Jennifer
    Juwara, Lamin
    Covey, Joseph M.
    Beumer, Jan H.
    Cristea, Mihaela C.
    Newman, Edward M.
    Koehler, Stephen
    Nieva, Jorge J.
    Garcia, Agustin A.
    Gandara, David R.
    Miller, Brandon
    Khin, Sonny
    Miller, Sarah B.
    Steinberg, Seth M.
    Rubinstein, Larry
    Parchment, Ralph E.
    Kinders, Robert J.
    Piekarz, Richard L.
    Kummar, Shivaani
    Chen, Alice P.
    Doroshow, James H.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (05) : 979 - 993
  • [2] Phase I trial of oral 5-fluoro-2′-deoxycytidine with oral tetrahydrouridine in patients with advanced solid tumors
    Coyne, G. O'Sullivan
    Chen, A. P.
    Kummar, S.
    Meehan, R. S.
    Collins, J.
    Zlott, J.
    Kelly, K.
    Lenz, H. J.
    Newman, E. M.
    Morgan, R.
    Juwara, L.
    Eiseman, J.
    Beumer, J. H.
    Tomaszewski, J.
    Doroshow, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : S90 - S90
  • [3] Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-5-Fluoro-2′-Deoxycytidine with Tetrahydrouridine in Solid Tumors
    Young, Colin R.
    Adler, Stephen
    Eary, Janet F.
    Lindenberg, M. Liza
    Jacobs, Paula M.
    Collins, Jerry
    Kummar, Shivaani
    Kurdziel, Karen A.
    Choyke, Peter L.
    Mena, Esther
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (04) : 492 - 496
  • [4] Restoration of p16INK4A expression in circulating tumor cells in patients with advanced solid tumors treated with deoxycytidine analogs and associated dynamic EMT phenotypic changes
    Wang, Lihua
    Miller, Brandon
    Khin, Sonny
    O'Sullivan-Coyne, Geraldine
    Chen, Alice P.
    Kummar, Shivaani
    Takebe, Naoko
    Ferry-Galow, Kate
    Parchment, Ralph E.
    Rubinstein, Larry
    Piekarz, Richard
    Newman, Edward M.
    Doroshow, James H.
    Kinders, Robert J.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [5] Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors - A potential broadly active regimen for advanced solid tumor malignancies
    Mani, S
    Vogelzang, NJ
    Bertucci, D
    Stadler, WM
    Schilsky, RL
    Ratain, MJ
    [J]. CANCER, 2001, 92 (06) : 1567 - 1576